Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016-2019 data.

To reduce Medicare prescription drug expenditures, the 2022 Inflation Reduction Act (IRA) allows the Centers for Medicare & Medicaid Services (CMS) to directly negotiate with drug manufacturers on Medicare prices of high-expenditure drugs (≥$200m annual spending) which meet certain eligibility criteria. However, it is unclear what proportion of high-expenditure drugs covered by Medicare, and attributable annual drug spending, would typically be eligible for CMS negotiations in a given year. We used historical Medicare drug spending data to determine how many high-expenditure drugs, and attributable drug spending, would have been eligible for CMS negotiations had the IRA been in effect from 2016-2019, while also determining which of the IRA's eligibility criteria is most restrictive. From 2016-2019, approximately one third (33.3% for Part B, 32.4% for Part D) of high-expenditure Medicare drugs would have been eligible for negotiation, with ineligible drugs accounting for 75.2% and 63.8% of spending on high-expenditure drugs in Medicare Part B and D, respectively. Most ineligible high-expenditure drugs were ineligible because they launched too recently. From 2016-2019, between 59 and 74 high-expenditure drugs were eligible per year, indicating that in some years there may not be enough eligible drugs for CMS to negotiate on the maximum number of drugs allowable by law. The IRA's current eligibility criteria may restrict CMS from being able to negotiate drug prices on approximately two-thirds of the high-expenditure drugs covered by Medicare and may not allow CMS to negotiate on the maximum number of drugs allowable by law. Congress could consider relaxing eligibility requirements for price negotiation, such as those pertaining to launch date recency, to ensure there are a sufficient number of high-expenditure drugs eligible for negotiation or make certain ineligible drugs contributing to significant annual Medicare spending eligible for negotiation on a case-by-case basis.

Qureshi O ，Ramachandran R ，Ross JS 《-》

Examining Opportunities to Increase Savings From Medicare Price Negotiations.

Reitsma MB ，Dusetzina SB ，Ballreich JM ，Trujillo AJ ，Mello MM ... -  《-》

Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.

Rome BN ，Nagar S ，Egilman AC ，Wang J ，Feldman WB ，Kesselheim AS ... -  《-》

Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025.

Cousin EM ，Sullivan SD ，Hansen RN ，Gabriel N ，Kirihennedige AS ，Hernandez I ... -  《-》

Why Does the Inflation Reduction Act Exclude Expensive Cancer Treatments in Price Negotiations?

Horn DM ，Jacobson M ，Alpert AE ，Duggan MG ... -  《-》